Purple Biotech (PPBT) Cash & Equivalents (2014 - 2026)
Purple Biotech (PPBT) reported Cash & Equivalents of $5.6 million for Q1 2026, down 24.78% year-over-year from $7.4 million in Q1 2025, and down 36.14% on a QoQ basis from $8.7 million in Q4 2025.
Purple Biotech (PPBT) has 11 years of Cash & Equivalents data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Cash & Equivalents fell 24.78% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 24.78% YoY) and the FY2025 annual result came in at $8.7 million, up 17.78% from the prior year.
- Cash & Equivalents eased to $5.6 million in Q1 2026 per PPBT's latest filing, from $8.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $15.0 million in Q4 2022 and bottomed at $5.6 million in Q1 2026.
- The 5-year median for Cash & Equivalents is $8.1 million (2024), against an average of $9.8 million.
- The widest annual swing landed in 2022, when Cash & Equivalents surged 38.02%; it then slumped 48.92% in 2024.
- Tracing PPBT's Cash & Equivalents over 5 years: stood at $15.0 million in 2022, then slipped by 3.6% to $14.5 million in 2023, then tumbled by 48.92% to $7.4 million in 2024, then rose by 17.78% to $8.7 million in 2025, then plunged by 36.14% to $5.6 million in 2026.
- Per Business Quant, the three latest PPBT Cash & Equivalents figures stand at $5.6 million (Q1 2026), $8.7 million (Q4 2025), and $7.4 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Purple Biotech | 3.58 Bn | 3.57 Bn | - | 5.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.57 Mn |
| Dec 31, 2025 | 8.72 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Jun 30, 2025 | 4.74 Mn |
| Mar 31, 2025 | 7.40 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Sep 30, 2024 | 5.44 Mn |
| Jun 30, 2024 | 6.52 Mn |
| Mar 31, 2024 | 9.99 Mn |
| Dec 31, 2023 | 14.49 Mn |
| Sep 30, 2023 | 15.10 Mn |
| Jun 30, 2023 | 17.20 Mn |
| Mar 31, 2023 | 21.88 Mn |
| Dec 31, 2022 | 15.03 Mn |
| Sep 30, 2022 | 11.07 Mn |
| Jun 30, 2022 | 10.89 Mn |
| Mar 31, 2022 | 23.54 Mn |
| Dec 31, 2021 | 10.89 Mn |
| Sep 30, 2021 | 11.25 Mn |
| Jun 30, 2021 | 10.54 Mn |
| Mar 31, 2021 | 10.20 Mn |
| Dec 31, 2020 | 11.25 Mn |
| Jun 30, 2020 | 63.00 Mn |
| Dec 31, 2019 | 4.39 Mn |
| Jun 30, 2019 | 2.76 Mn |
| Dec 31, 2018 | 5.16 Mn |
| Jun 30, 2018 | 5.36 Mn |
| Dec 31, 2017 | 3.95 Mn |
| Jun 30, 2017 | 6.76 Mn |
| Dec 31, 2016 | 6.76 Mn |
| Jun 30, 2016 | 10.56 Mn |
| Dec 31, 2015 | 10.56 Mn |
| Sep 30, 2015 | 981,000.00 |
| Dec 31, 2014 | 1.31 Mn |
| Sep 30, 2014 | 2.42 Mn |